Human monoclonal antibodies to FC alpha receptor (CD89)
Human monoclonal antibodies which bind specifically to Fc alpha receptor (CD89), including monoclonal antibodies which react specifically to Fc receptor for IgA of human effector cells are disclosed. The binding agents, e.g., antibodies are useful for targeting human effector cells (e.g. macrophages) against a target cell (e.g. a cancer cell, an infectious agent, etc.). For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc-alpha receptor antibody and the binding region of a target-specific antibody. Targeted effector cells can specifically lyse target cells.
1. An isolated human monoclonal antibody, or antigen binding portion thereof, selected from the group consisting of:
(a) an antibody, or antigen binding portion thereof, comprising (i) a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising amino acid residues 30–35, amino acid residues 50–66, and amino acid residues 99–108 of SEQ ID NO:2, respectively; and (ii) a light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising amino acid residues 24–34, amino acid residues 50–56, and amino acid residues of 89–97 of SEQ ID NO:4, respectively, wherein the antibody binds to human CD89; and
(b) an antibody, or antigen binding portion thereof, comprising (i) a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising amino acid residues 31–35, amino acid residues 50–66, and amino acid residues 99–108 of SEQ ID NO:6, respectively; and (ii) a light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising amino acid residues 24–35, amino acid residues 51–57, and amino acid residues 90–99 of SEQ ID NO:8, respectively, wherein the antibody binds to human CD89.
2. An isolated human monoclonal antibody, or antigen binding portion thereof, comprising a human heavy chain variable region and a human light chain variable region, wherein:
(a) the human heavy chain variable region comprises the amino acid sequence of SEQ ID NO:2;
(b) the human light chain variable region comprises the amino acid sequence of SEQ ID NO:4;
(c) the antibody binds to human CD89;
(d) the antibody does not activate complement upon binding to CD89 in vivo; and
(e) the antibody does not block IgA binding to CD89.
3. An isolated human monoclonal antibody, or antigen binding portion thereof, comprising a human heavy chain variable region and a human light chain variable region, wherein:
(a) the human heavy chain variable region comprises the amino acid sequence of SEQ ID NO:6;
(b) the human light chain variable region comprises the amino acid sequence of SEQ ID NO:8;
(c) the antibody binds to human CD89;
(d) the antibody does not activate complement upon binding to CD89 in vivo; and
(e) the antibody does not block IgA binding to CD89.
4. An isolated human monoclonal antibody, or antigen binding portion thereof, comprising human heavy chain and human light chain variable regions comprising the amino acid sequences shown in SEQ ID NO:2 and SEQ ID NO:4, respectively.
5. An isolated human monoclonal antibody, or antigen binding portion thereof, comprising human heavy chain and human light chain variable regions comprising the amino acid sequences shown in SEQ ID NO:6 and SEQ ID NO:8, respectively.
6. A composition comprising a pharmaceutically acceptable carrier and an isolated human monoclonal antibody, or antigen binding portion thereof, comprising:
(a) a heavy chain variable region derived from a human germline V H 3–30.3 gene; and
(b) a light chain variable region derived from a human germline V K L18 gene or V K A27 gene;
wherein the human antibody binds human CD89.
7. An isolated human monoclonal antibody, or antigen binding portion thereof, comprising:
(a) a heavy chain variable region derived from a human germline V H 3-30.3 gene; and
(b) a light chain variable region is derived from a human germline V K L18 gene;
wherein the human antibody binds human CD89 and wherein the antibody does not activate complement upon binding to CD89 in vivo.
8. The antibody, or antigen binding portion thereof, of claim 1 , 2 , or 3 , wherein the antigen binding portion thereof, is a Fab fragment or a single chain antibody.
9. A hybridoma comprising a B cell obtained from a transgenic nonhuman animal having a genome comprising a human heavy chain transgene and a light chain transgene fused to an immortalized cell, wherein the hybridoma produces a detectable amount of the antibody, or antigen binding portion thereof, of claim 1 , 2 , or 3 .
10. A transfectoma comprising nucleic acids encoding a human heavy chain and a human light chain, wherein the transfectoma produces a detectable amount of the antibody, or antigen binding portion thereof, of claim 1 , 2 , or 3 .
11. A method of producing the antibody, or antigen binding portion thereof, of claim 1 , 2 , or 3 , comprising:
immunizing a transgenic nonhuman animal having a genome comprising a human heavy chain transgene and a human light chain transgene with human CD89 or a cell expressing human CD89, such that antibodies are produced by B cells of the animal;
isolating B cells of the animal;
fusing the B cells with myeloma cells to form immortal, hybridoma cells that secrete human monoclonal antibodies specific for CD89; and
isolating the human monoclonal antibodies specific for CD89 from the culture supernatant of the hybridoma.
12. A composition comprising the antibody, or antigen binding portion thereof, of claim 1 , 2 , 3 and a pharmaceutically acceptable carrier.
13. A composition comprising a combination of two or more antibodies, or antigen binding portions thereof, of claim 1 , 2 , or 3 , wherein each of said antibodies, or antigen binding portions thereof, binds to a distinct epitope of human CD89.
14. The composition of claim 12 further comprising a cytotoxic agent.
15. A method of detecting the presence of CD89 or a cell expressing CD89 in a sample, comprising:
contacting the sample with the antibody, or antigen binding portion thereof, of claim 1 , 2 , or 3 under conditions that allow for formation of a complex between the antibody, or antigen binding portion thereof, and CD89; and
detecting the formation of the complex.
16. An isolated human monoclonal antibody, or antigen binding portion thereof, comprising:
(a) a heavy chain variable region derived from a human germline V H 3- 303 gene;
(b) a light chain variable region derived from a human germline V K A27 gene;
wherein the human antibody binds human CD89.